Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.

Adipic acid (PubChem CID: 196) Celecoxib Celecoxib (PubChem CID: 2662) Citric acid (PubChem CID: 311) Contact angle Eutectic Evaporation crystallization Fumaric acid (PubChem CID: 444972) Malic acid (PubChem CID: 525) Nicotinamide (PubChem CID: 936) Phase diagram Saccharin (PubChem CID: 5143) Succinic acid (PubChem CID: 1110) Tammann’s Triangle Urea (PubChem CID: 62705)

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
10 Jan 2019
Historique:
received: 25 08 2018
revised: 16 10 2018
accepted: 17 10 2018
pubmed: 23 10 2018
medline: 4 4 2019
entrez: 23 10 2018
Statut: ppublish

Résumé

Celecoxib (CEL) is a selective cyclooxygenase-2 (COX-2) inhibitor therapeutically indicated for the treatment of rheumatoid arthritis, osteoarthritis, acute pain, and inflammation. However, its poor solubility and dissolution rate significantly hinders its broader application. In this study, eutectic mixtures, as binary pharmaceutical compositions of CEL with adipic acid (ADI) and saccharin (SAC), were identified through a phase diagram and Tammann's triangle intended to improve the wettability and dissolution rate of poorly water-soluble CEL. The contact angles at 0s in the liquid-solid interface were approximately θs (theta) 79.7 ± 0.50° and 86.65 ± 0.45° for CEL-ADI and CEL-SAC, respectively, which were much lower than the value obtained for CEL (92.05 ± 0.75° θ). Moreover, a comparison of the disk intrinsic dissolution rate and powder dissolution properties demonstrated that eutectic mixtures significantly increased the dissolution rate compared with CEL and physical mixtures. A general relationship was elucidated and indicated that the dissolution rate was increased as the contact angle decreased (correlation coefficient, r = 0.9966 ± 0.0031). Therefore, CEL-ADI and CEL-SAC eutectics may offer a novel formulation strategy to enhance the solubility and oral bioavailability of CEL.

Identifiants

pubmed: 30347274
pii: S0378-5173(18)30784-1
doi: 10.1016/j.ijpharm.2018.10.044
pii:
doi:

Substances chimiques

Adipates 0
Cyclooxygenase 2 Inhibitors 0
Excipients 0
adipic acid 76A0JE0FKJ
Saccharin FST467XS7D
Celecoxib JCX84Q7J1L

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-71

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Sang-Min Hyun (SM)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Benjamin Joon Lee (BJ)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Sharif Md Abuzar (SM)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Soohun Lee (S)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Yechan Joo (Y)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Seung-Hyeon Hong (SH)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Han Kang (H)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.

Kyung-Ae Kwon (KA)

Dae Hwa Pharmaceutical Co., Ltd., 2145 Nambusunhwan-ro, Seocho-gu, Seoul 06699, Republic of Korea.

Sitaram Velaga (S)

Pharmaceutical Research, Division of Medical Sciences, Department of Health Science, Luleå University of Technology, Luleå SE-97187, Sweden. Electronic address: sitram.velaga@ltu.se.

Sung-Joo Hwang (SJ)

College of Pharmacy, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea; Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea. Electronic address: sjh11@yonsei.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Inclusion Bodies Solubility Recombinant Proteins Detergents Protein Denaturation
Nanoparticles Needles Polylactic Acid-Polyglycolic Acid Copolymer Polyethylene Glycols Curcumin

Classifications MeSH